T cell lymphoblastic lymphoma (T-LBL) accounts for 30% of all childhood non-Hodgkin's lymphomas (NHL) in Japan. Twenty-nine patients with T-LBL in stages III and IV were eligible for and enrolled in the JACLS NHL-T98 trial (1998-2002), and 72 patients with T-ALL were enrolled in the JACLS ALL-T97 trial (1997-2001). The 10-year overall survival (OS) (61.1 ± 11.5%) and the 10-year event-free survival (EFS) (44.4 ± 11.7%) of stage III LBL were lower than those of other diseases, and the OS and EFS were nearly the same when comparing stage IV LBL and ALL (OS: stage IV LBL, 80.0 ± 12.7% vs. ALL, 80.2 ± 4.9%; EFS: stage IV, LBL 70.0 ± 14.5% vs. ALL, 70.7 ± 5.5%). Outcomes were worse for stage III LBL than for stage IV LBL or T-ALL. Given that the treatment results of T-ALL and LBL stage IV did not differ when compared with previous reports, LBL stage III in Japanese children may differ from LBL stage III in children in other countries.
All Science Journal Classification (ASJC) codes